Experienced in Acquired Amegakaryocytic Thrombocytopenia

Dr. Lauri M. Burroughs

Pediatric Hematology Oncology
4800 Sand Point Way Ne, 
Seattle, WA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
25 Years of Experience
Experienced in Acquired Amegakaryocytic Thrombocytopenia
4800 Sand Point Way Ne, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Lauri Burroughs is a Pediatric Hematologist Oncology provider in Seattle, Washington. Dr. Burroughs has been practicing medicine for over 25 years and is rated as an Experienced provider by MediFind in the treatment of Acquired Amegakaryocytic Thrombocytopenia. Her top areas of expertise are Severe Combined Immunodeficiency (SCID), Wiskott-Aldrich Syndrome, Shwachman-Diamond Syndrome, Aplastic Anemia, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 55 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article and participated in 1 clinical trial in the study of Acquired Amegakaryocytic Thrombocytopenia.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatrics in WA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

PacificSource
  • PPO
Premera
  • EPO
  • PPO

Locations

4800 Sand Point Way Ne, Seattle, WA 98105

Additional Areas of Focus

Dr. Burroughs has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Targeted Astatine-211-Labeled BC8-B10 Monoclonal Antibody as Reduced Intensity Conditioning for Nonmalignant Diseases
Targeted Astatine-211-Labeled BC8-B10 Monoclonal Antibody as Reduced Intensity Conditioning for Nonmalignant Diseases
Enrollment Status: Recruiting
Publish Date: August 15, 2025
Intervention Type: Drug, Radiation, Procedure, Biological
Study Phase: Phase 1/Phase 2
A Randomized Trial of Low Versus Moderate Exposure Busulfan for Infants With Severe Combined Immunodeficiency (SCID) Receiving TCRαβ+/CD19+ Depleted Transplantation: A Phase II Study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC)
A Randomized Trial of Low Versus Moderate Exposure Busulfan for Infants With Severe Combined Immunodeficiency (SCID) Receiving TCRαβ+/CD19+ Depleted Transplantation: A Phase II Study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC)
Enrollment Status: Active_not_recruiting
Publish Date: November 21, 2025
Intervention Type: Drug, Device
Study Drug: Busulfan
Study Phase: Phase 2
A Pilot Feasibility Study of Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants Using a Self-Inactivating Lentiviral Vector to Transduce Autologous CD34+ Hematopoietic Cells
A Pilot Feasibility Study of Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants Using a Self-Inactivating Lentiviral Vector to Transduce Autologous CD34+ Hematopoietic Cells
Enrollment Status: Suspended
Publish Date: November 10, 2025
Intervention Type: Device, Genetic, Drug
Study Drugs: Busulfan, Autologous CD34-Positive GammaC-Transduced Lentiviral Bone Marrow Cells
Study Phase: Phase 1/Phase 2
Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for the Treatment of Bone Marrow Failure Diseases
Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for the Treatment of Bone Marrow Failure Diseases
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Phase: Phase 2
Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia
Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia
Enrollment Status: Completed
Publish Date: May 11, 2025
Intervention Type: Drug, Procedure, Radiation
Study Phase: Not Applicable
Radiation- and Alkylator-free Hematopoietic Cell Transplantation for Bone Marrow Failure Due to Dyskeratosis Congenita / Telomere Disease
Radiation- and Alkylator-free Hematopoietic Cell Transplantation for Bone Marrow Failure Due to Dyskeratosis Congenita / Telomere Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 31, 2025
Intervention Type: Drug, Biological
Study Drugs: Alemtuzumab, Fludarabine, Cyclosporine, Mycophenolate Mofetil
Study Phase: Phase 2
A Study Evaluating BPX-501 T Cells and AP1903 for Prevention of Graft Versus Host Disease (GVHD) After Haploidentical, Related, T Cell-Depleted Hematopoietic Cell Transplantation for Non-Malignant Diseases
A Study Evaluating BPX-501 T Cells and AP1903 for Prevention of Graft Versus Host Disease (GVHD) After Haploidentical, Related, T Cell-Depleted Hematopoietic Cell Transplantation for Non-Malignant Diseases
Enrollment Status: Terminated
Publish Date: March 25, 2024
Intervention Type: Biological
Study Drugs: BPX-501, Rimiducid
Study Phase: Phase 1
Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Enrollment Status: Active_not_recruiting
Publish Date: July 12, 2022
Intervention Type: Biological, Drug
Study Drugs: BPX-501 T Cells, Rimiducid
Study Phase: Phase 1/Phase 2
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Enrollment Status: Unknown
Publish Date: September 02, 2021
Allogeneic Hematopoietic Cell Transplantation for Patients With Nonmalignant Inherited Disorders Using a Treosulfan Based Preparative Regimen
Allogeneic Hematopoietic Cell Transplantation for Patients With Nonmalignant Inherited Disorders Using a Treosulfan Based Preparative Regimen
Enrollment Status: Completed
Publish Date: August 13, 2021
Intervention Type: Procedure, Drug, Other, Biological, Radiation
Study Drugs: Anti-Thymocyte Globulin, Cyclosporine, Fludarabine, Methotrexate, Mycophenolate Mofetil, Tacrolimus, Treosulfan
Study Phase: Phase 2
HLA-Haploidentical Related Marrow Grafts for the Treatment of Primary Immunodeficiencies and Other Nonmalignant Disorders Using Conditioning With Low-Dose Cyclophosphamide, TBI and Fludarabine and Postgrafting Cyclophosphamide
HLA-Haploidentical Related Marrow Grafts for the Treatment of Primary Immunodeficiencies and Other Nonmalignant Disorders Using Conditioning With Low-Dose Cyclophosphamide, TBI and Fludarabine and Postgrafting Cyclophosphamide
Enrollment Status: Terminated
Publish Date: January 26, 2021
Intervention Type: Drug, Radiation, Procedure, Other
Study Phase: Phase 2
A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902)
A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902)
Enrollment Status: Unknown
Publish Date: November 12, 2020
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)
Enrollment Status: Enrolling_by_invitation
Publish Date: November 10, 2020
Analysis of Patients Treated for Wiskott-Aldrich Syndrome Since January 1, 1990 (RDCRN PIDTC-6904)
Analysis of Patients Treated for Wiskott-Aldrich Syndrome Since January 1, 1990 (RDCRN PIDTC-6904)
Enrollment Status: Completed
Publish Date: August 10, 2020
View 13 Less Clinical Trials

55 Total Publications

Post Hematopoietic Cell Transplantation Maintenance Therapy with Low-Dose Azacitidine in a Pediatric Population with High-Risk Myeloid Malignancies.
Post Hematopoietic Cell Transplantation Maintenance Therapy with Low-Dose Azacitidine in a Pediatric Population with High-Risk Myeloid Malignancies.
Journal: Transplantation and cellular therapy
Published: September 22, 2025
Similar Doctors
Advanced in Acquired Amegakaryocytic Thrombocytopenia
Dr. Amy Geddis
Pediatric Hematology Oncology
Advanced in Acquired Amegakaryocytic Thrombocytopenia
Dr. Amy Geddis
Pediatric Hematology Oncology
4800 Sand Point Way Ne, 
Seattle, WA 
 (0.1 miles away)
206-987-2106
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Amy Geddis is a Pediatric Hematologist Oncology provider in Seattle, Washington. Dr. Geddis is rated as an Advanced provider by MediFind in the treatment of Acquired Amegakaryocytic Thrombocytopenia. Her top areas of expertise are Shwachman-Diamond Syndrome, Aplastic Anemia, Immune Thrombocytopenic Purpura (ITP), Acquired Amegakaryocytic Thrombocytopenia, and Splenectomy.

Advanced in Acquired Amegakaryocytic Thrombocytopenia
Dr. Jay F. Sarthy
Pediatric Hematology Oncology
Advanced in Acquired Amegakaryocytic Thrombocytopenia
Dr. Jay F. Sarthy
Pediatric Hematology Oncology

The Association Of Chrmc And University Physicians

4800 Sand Point Way Ne, 
Seattle, WA 
 (0.1 miles away)
206-526-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jay Sarthy is a Pediatric Hematologist Oncology provider in Seattle, Washington. Dr. Sarthy is rated as an Advanced provider by MediFind in the treatment of Acquired Amegakaryocytic Thrombocytopenia. His top areas of expertise are Acute Megakaryoblastic Leukemia, Acquired Amegakaryocytic Thrombocytopenia, Brain Stem Cancer, Ewing Sarcoma, and Bone Marrow Transplant.

Experienced in Acquired Amegakaryocytic Thrombocytopenia
Dr. Soheil Meshinchi
Pediatric Hematology Oncology
Experienced in Acquired Amegakaryocytic Thrombocytopenia
Dr. Soheil Meshinchi
Pediatric Hematology Oncology
1100 Fairview Ave N, Box 358080 - D4-100, 
Seattle, WA 
 (3.3 miles away)
206-667-4077
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Soheil Meshinchi is a Pediatric Hematologist Oncology provider in Seattle, Washington. Dr. Meshinchi is rated as a Distinguished provider by MediFind in the treatment of Acquired Amegakaryocytic Thrombocytopenia. His top areas of expertise are Childhood Acute Myeloid Leukemia, Acute Megakaryoblastic Leukemia, Leukemia, Trisomy 3 Mosaicism, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Burroughs's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 11 Advanced Conditions
    View All 17 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile